StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.40 | $7.21 | -2.57% | 0.5M |
| 05-12 | $7.46 | $12.01 | +60.99% | 19.4M |
| 05-13 | $14.37 | $12.14 | -15.52% | 1.8M |
| 05-14 | $11.70 | $9.56 | -18.29% | 0.5M |
| 05-15 | $9.21 | $13.63 | +47.99% | 1.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for ERNA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for ERNA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 | Q2 2020 2020-06-30 | Q1 2020 2020-03-31 |
|---|---|---|---|---|
Revenue | $5.80M | $4.63M | $3.15M | $2.39M |
Operating Income | $-7.25M | $-5.04M | $-3.03M | $-1.01M |
Net Income | $-7.29M | $-5.07M | $-3.05M | $-1.02M |
EPS (Diluted) | $-0.41 | $-0.29 | $-0.17 | $-0.06 |
Total Assets | $12.91M | $5.05M | $6.79M | $11.01M |
Total Liabilities | $5.25M | $4.56M | $4.86M | $7.17M |
Cash & Equivalents | $777.00K | $1.71M | $2.23M | $2.22M |
Free Cash Flow OCF − CapEx | $-8.14M | $-6.49M | $-4.08M | $-1.88M |
Shares Outstanding | 0 | 2.95M | 2.94M | 2.93M |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.